Pharmafile Logo
Pharmafocus logo
Advanced Search

Nuclera gains £1.14m funding from Innovate UK

June 7, 2024
Research and Development Innovate UK, Nuclera, Pharmacy, grants

Nuclera has announced that it has been awarded two grants from Innovate UK, totalling £1.14m.

News
yunus-tug-lnfgdbcajxu-unsplash

FDA approves Geron’s Rytelo for treatment of MDS with transfusion-dependent anaemia

June 7, 2024
Medical Communications FDA, Geron, Haematology, anaemia, mds

Geron Corporation has announced that the US Food and Drug Administration (FDA) has approved Rytelo (imetelstat) for the treatment of …

News

AbbVie initiates phase 3 multiple myeloma trial

June 6, 2024
Medical Communications ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma

AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess …

News

Syngene launches new platform for protein production

June 6, 2024
Research and Development ExcellGene, Pharmacy, Syngene, platform, protein production

Syngene has announced the launch of its new protein production platform, which will utilise a cell line and transposon-based technology …

News

Gilead shares results from two-year analysis of phase 3 study in primary biliary cholangitis

June 5, 2024
Research and Development Gilead, Hepatology, clinical trials, primary biliary cholangitis, seladelpar

Gilead has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary …

News
testalize-me-0je8ynv4mis-unsplash

Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment

June 5, 2024
Research and Development Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma

Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide …

News

Quince Therapeutics gains FDA Fast Track Designation for EryDex System

June 4, 2024
Medical Communications EryDex, FDA, Quince Therapeutics, Rare Diseases, fast track designation

Quince Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for its EryDex …

News

Oryzon Genomics announces publication of phase 2a ALICE trial results

June 4, 2024
Medical Communications AML, Oncology, Oryzon genomics, acute myeloid leukaemia, clinical trial

Oryzon Genomics has announced that the final results from its phase 2a ALICE study have been published online in The …

News

CHMP recommends AstraZeneca’s Tagrisso for approval for lung cancer treatment

June 3, 2024
Medical Communications CHMP, EMA, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that Tagrisso (osimertinib) alongside pemetrexed and platinum-based chemotherapy, has been recommended for approval in the EU for …

News

Gilead and Arcus announce results from colorectal cancer treatment trial

June 3, 2024
Research and Development Arcus, Gilead, Oncology, clinical trial, colorectal cancer

Gilead Sciences and Arcus Biosciences have announced new data from cohort B of ARC-9, a phase 1b/2 study which aims …

News

AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC

May 31, 2024
Medical Communications AbbVie, EMA, Gastrointestinal tract, Skyrizi, ulcerative colitis

AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …

News

Merck to acquire EyeBio for an upfront $1.3bn

May 31, 2024
Business Services EyeBio, Merck, Opthalmology, acquisition, ophthalmology

Merck, known as MSD outside of the US and Canada, and EyeBiotech Limited, have announced that the two companies have …

News

Eli Lilly and UNICEF expand support for young people at risk of noncommunicable diseases

May 30, 2024
Medical Communications Eli Lilly, Pharmacy, Unicef, investment, noncommunicable diseases

Eli Lilly has announced that it will donate $6.5m to the United States Fund for UNICEF in order to expand …

News

Full-Life Technologies’ IND application for prostate cancer cleared by FDA

May 30, 2024
Medical Communications Full-Life Technologies, IND, Oncology, prostate cancer

Full-Life Technologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application …

News

Sanofi’s Sarclisa accepted for FDA priority review

May 29, 2024
Medical Communications FDA, Oncology, Sanofim, Sarclisa, multiple myeloma, priority review

Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …

News

Merck shares data from phase 3 trial of Keytruda for TNBC treatment

May 29, 2024
Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda

Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …

News

AstraZeneca shares results from phase 3 TROPION-Lung01 trial

May 28, 2024
Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan

AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …

News

Eli Lilly increases manufacturing investment to $9bn at new Indiana site

May 28, 2024
Manufacturing and Production Diabetes, Eli Lilly, Indiana, investment, manufacturing

Eli Lilly has announced that it has more than doubled its investment at its Lebanon, Indiana, US manufacturing site with …

News

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024
Research and Development Boehringer Ingelheim, Cancer, Cardiology, OSE Immunotherapeutics, cardio-renal-metabolic diseases

OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership. The expansion includes two new projects …

News

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024
Research and Development AstraZeneca, Cancer, Oncology, nona biosciences, targeted therapies

Nona Biosciences and AstraZeneca have announced that the two companies have entered into a license agreement for preclinical monoclonal antibodies, …

News

BioGen to acquire Human Immunology Biosciences for $1.15bn

May 23, 2024
Business Services Biogen, HI-Bio, Immunology, acquisition, immunology

BioGen and Human Immunology Biosciences (HI-Bio) have announced that they have entered into a definitive agreement for Biogen to acquire …

News

Latest content

Nuclera gains £1.14m funding from Innovate UK

June 7, 2024

FDA approves Geron’s Rytelo for treatment of MDS with transfusion-dependent anaemia

June 7, 2024

AbbVie initiates phase 3 multiple myeloma trial

June 6, 2024

Syngene launches new platform for protein production

June 6, 2024

Gilead shares results from two-year analysis of phase 3 study in primary biliary cholangitis

June 5, 2024